Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer.

ASCO SIGN IN

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Meetings

Abstracts

2005 ASCO Annual Meeting

Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer.

Sub-category:

Adjuvant Therapy

Category:

Breast Cancer

Meeting:

2005 ASCO Annual Meeting

Abstract No:

853

Citation:

Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 853

Author(s):

G. Perez Manga, M. Méndez, M. I. Palomero, R. Quibén, J. Belón

Abstract:

Background: Previous studies suggest that chemotherapy + surgery + radiotherapy combined treatment has a high survival rate in patients with locally advanced or inflammatory breast cancer. Primary objective was evaluate response rate. Secondary objectives were time to progression, duration of response and toxicity profile of neoadjuvant chemotherapy T, A and X in patients with locally advanced or inflammatory breast cancer. Methods: Eligibility criteria: Patients with histologically confirmed locally advanced or inflammatory breast cancer, ECOG PS ≤ 2, age ≤ 75 years and LVEF > 50%. Prior systemic therapy, surgery or radiotherapy for breast cancer was not allowed. Patients with invasive bilateral breast cancer were not included. Treatment: T (30 mg/m²) iv day 1, 8 and 15, A (50 mg/m²) iv day 1 and X (1500 mg/m²o. d.) days 1-14, in a 4 weeks course. This scheme was repeated up to 4 cycles followed by surgery. According to investigator criteria and response, the patients will receive a maximum of two more cycles. Radiotherapy and hormonal treatment are allowed depending on molecular markers. Expression of markers was performed by Inmunohistochemistry before chemotherapy. Results: twenty-eight patients were included in this interim analysis, with a median age of 48 years (35-68). The ECOG PS was 0 in 38.5% of patients. Hormonal receptor status was ER+ 44% and PR+ 33%. To date, a total of 95 cycles (median 4, range 2-4) were administered. Median relative dose intensity was 90% for T and A, and 92% for X. Thirteen patients are still undergoing treatment; of 21 evaluable patients for efficacy, 6 achieved CR and 15 PR resulting in an ORR of 100%. Surgery was performed in 20 patients: three (15.0%) of them achieved pathological CR. All patients were evaluable for toxicity. Grade III/IV toxicity per patient was neutropenia (75.0%), leucopenia (39.3%), febrile neutropenia (10.7%); diarrhea (14.3%), mucositis (10.7%), nauseas / vomiting (7.1%) and asthenia (3.6%). Conclusions: T, A and X every 28 days administered during 4 cycles as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer is an active regimen.

Associated Presentation(s):

No items found.

Other Abstracts in this Sub-Category:

		1. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women’s Intervention Nutrition Study (WINS) Meeting: 2005 ASCO Annual Meeting Abstract No: 10 First Author: R. T. Chlebowski Category: Breast Cancer - Adjuvant Therapy
		2. Disseminated tumor cells (DTC) in bone marrow (BM) and clinical outcome: Final results of pooled analysis on 10-year survival of 4,703 breast cancer patients Meeting: 2005 ASCO Annual Meeting Abstract No: 502 First Author: S. Braun Category: Breast Cancer - Adjuvant Therapy
		3. Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue Meeting: 2005 ASCO Annual Meeting Abstract No: 505 First Author: N. Harbeck Category: Breast Cancer - Adjuvant Therapy
		More...

Abstracts by G. Perez Manga:

		1. Phase II study of neoadjuvant treatment with docetaxel, capecitabine, and trastuzumab in HER-2-positive locally advanced or inflammatory breast cancer: TXH trial. Meeting: 2009 ASCO Annual Meeting Abstract No: e11581 First Author: G. Perez Manga Category: Breast Cancer--Local-Regional and Adjuvant Therapy - Adjuvant Therapy
		2. Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer (LABC). Meeting: 2006 ASCO Annual Meeting Abstract No: 10678 First Author: G. Perez Manga Category: Breast Cancer - Adjuvant Therapy
		3. Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer. Meeting: 2005 ASCO Annual Meeting Abstract No: 853 First Author: G. Perez Manga Category: Breast Cancer - Adjuvant Therapy
		More...

Presentations by G. Perez Manga:

No items found.

Educational Book Manuscripts by G. Perez Manga:

No items found.